Stoked Bio

Stoked Bio is a full-stack drug discovery, development, and validation company focused on discovering small molecules for cancers that are otherwise resistant to current treatments. A key differentiator is their exclusive access to multiple proprietary AI datasets trained on proprietary disease-specific phenotypic and genotypic data generated in their wet lab, which allows for the rapid identification and synthesis of promising compounds with proven manufacturability. Stoked Bio's first candidate, a small molecule for recurrent glioblastoma, demonstrates selective killing of target cancer cells in cell culture.